DaVita Inc. (NYSE:DVA) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company cut its stake in shares of DaVita Inc. (NYSE:DVA) by 13.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,251 shares of the company’s stock after selling 5,993 shares during the period. The Manufacturers Life Insurance Company’s holdings in DaVita were worth $6,434,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in DVA. Transcendent Capital Group LLC purchased a new stake in DaVita during the 3rd quarter worth approximately $25,000. Blue Trust Inc. grew its stake in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares in the last quarter. Family Firm Inc. purchased a new stake in shares of DaVita during the second quarter worth $43,000. Friedenthal Financial acquired a new stake in shares of DaVita in the second quarter valued at $48,000. Finally, Point72 Hong Kong Ltd purchased a new position in DaVita in the second quarter valued at $68,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of analyst reports. Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial increased their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and an average price target of $161.80.

DaVita Stock Down 1.2 %

DaVita stock opened at $161.39 on Friday. The stock has a 50 day moving average of $158.65 and a two-hundred day moving average of $149.93. DaVita Inc. has a twelve month low of $103.40 and a twelve month high of $169.51. The stock has a market capitalization of $13.23 billion, a price-to-earnings ratio of 17.52, a PEG ratio of 0.93 and a beta of 0.90. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same quarter last year, the firm earned $2.85 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. As a group, research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Activity

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 2.00% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.